Please assess the completion status of the following clinical trial:

Trial Title: Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seropositive for HIV~* Age 18-70~* Report average of at least twice weekly heavy drinking~* Willing to reduce drinking to non-hazardous levels~* Verbal Intelligence Quotient (Verbal IQ) of 80 or higher~* Willing to provide signed informed consent~* Willing to nominate an individual to help locate the participant's whereabouts for follow-up~* If female: non-lactating and practicing a reliable method of birth control~Exclusion Criteria:~* Current clinically significant and/or uncontrolled physical disease (e.g., pancreatitis, diabetes)~* History of nephrolithiasis~* Severe psychiatric illness (i.e., psychosis or mania)~* Current diagnosis of drug abuse or dependence (other than nicotine abuse/dependence and cannabis abuse)~* Current diagnosis of alcohol dependence (AD) too severe for participation in a trial in which the goal is reduced drinking~* Gross cognitive impairment~* Glaucoma~* Serious/confounding neurological disease (e.g, stroke, seizure)~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate + Medical Management (Type: EXPERIMENTAL): Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
- Placebo Pill + Medical Management (Type: PLACEBO_COMPARATOR): Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit

Based on this trial design, predict the completion outcome and termination type (if applicable).